Clinical trials: Clinically Isolated Syndrome
Clinically Isolated Syndrome, Relapsing-Remitting Multiple Sclerosis
Mitochondrial Dysfunction and Disease Progression
While the last several years have seen great strides in the treatment of relapsing forms of MS, progressive MS, responsible for the majority of MS-related disability, lags far behind.
- Conditions
- Clinically Isolated Syndrome, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Trial name
- NCT02549703
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Relapsing Remitting Multiple Sclerosis, Clinically Isolated Syndrome
Clinical Importance of Glucose Regulation in Relapsing MS
The purpose of this study is to assess the relationship of blood glucose levels in persons with Multiple Sclerosis (MS) who have experienced a relapse and will be receiving intravenous steroids for the relapse, to their recovery…
- Trial name
- NCT03004079
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Virginia
Clinically Isolated Demyelinating Syndromes, Multiple Sclerosis
Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI
Clinically isolated demyelinating syndromes (CIS) can evolve into multiple sclerosis (MS). Cognitive deficiencies could occur at this early stage and concern mainly information processing speed (IPS) and their mechanisms are not…
- Conditions
- Clinically Isolated Demyelinating Syndromes, Multiple Sclerosis, Cognitive Deficiencies, Brain MRI
- Trial name
- SCI-COG (NCT01865357)
- Testing
- Brain MRI - Clinical and cognitive evaluation, Eye movement
- Where
- France
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™
This is a Phase 4, interventional, multicenter study of subcutaneous Rebif® (interferon beta-1a) using RebiSmart™ device to assess effectiveness and adherence of treatment in subjects with clinically isolated syndrome (CIS) or…
- Trial name
- PROCEED (NCT02254304)
- Testing
- Rebif
- Where
- Germany
- Volunteers
- 106 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Clinically Isolated Syndrome, Multiple Sclerosis
Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome
The primary purpose of this study is to assess the immune response to vitamin D supplementation at two doses (5,000 IU and 10,000 IU daily) in both healthy controls and patients with clinically isolated syndrome compared to…
- Trial name
- CISAVID (NCT01728922)
- Testing
- 5000IU vitamin D, 10000IU vitamin D
- Where
- Ireland
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University College Dublin
Multiple Sclerosis, Clinically Isolated Syndrome
AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS
The definition of the most 'at-risk' population within highly susceptible groups would provide an opportunity for preemptive therapeutics.
- Trial name
- ARMS (NCT00617383)
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Multiple Sclerosis, Clinically Isolated Syndrome
Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)
REFLEXION is a double blind extension of the study 27025 (NCT00404352) (REFLEX). The purpose of the study is to obtain long-term follow-up data in subjects with clinically definite multiple sclerosis (MS) and subjects with a…
- Trial name
- REFLEXION (NCT00813709)
- Testing
- RNF
- Where
- 57 sites in Argentina, Austria and 22 more
- Volunteers
- 402 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Clinically Isolated Syndromes, Early Single Relapse of Multiple Sclerosis
Minocycline in Clinically Isolated Syndromes (CIS)
The aim of the trial is to demonstrate that 100 mg of oral minocycline twice daily reduces the conversion of CIS to McDonald Criteria MS (McDMS) by an absolute 25% as compared to placebo, over a 6 month follow-up period (primary…
- Trial name
- MinoCIS (NCT00666887)
- Testing
- Minocycline
- Where
- 12 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Dr. Luanne Metz
Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
This study will look at the blood and cerebrospinal fluid of consented participants who either have early stage multiple sclerosis (clinically isolated syndrome) or who have later stage (secondary progressive multiple sclerosis)…
- Conditions
- Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Clinically Isolated Syndrome
- Trial name
- NCT01737372
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- John F. Foley, MD
Acute Exacerbation of Remitting Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)
Patients with an acute exacerbation of Relapsing-Remitting Multiple Sclerosis or with Clinically Isolated Syndrome receive either one single infusion of Nanocort or three daily infusions of SoluMedrol.
- Trial name
- NCT01039103
- Testing
- PEG-liposomal prednisolone sodium phosphate, Methylprednisolone
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 15 people
- Sponsor
- Lakefront Biotherapeutics NV
Multiple Sclerosis - Relapsing Remitting, Clinically Isolated Syndrome, CNS Demyelinating
DTI in Children With Multiple Sclerosis
This is a prospective, non-randomised, non-blinded, single center study of children and adolescents with multiple sclerosis and clinically isolated syndrome to detect differences or early changes in diffusion-weighted imaging…
- Trial name
- NCT02361697
- Testing
- DTI-MRI
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Clinically Isolated Syndrome
Longitudinal Study in Clinically Isolated Syndrome (CIS) Patients Treated With Interferon Beta
The aim of this study is to evaluate the role of cognitive disorders and quality of life in patients with CIS, considered as high risk to develop an MS, treated with interferon Beta.
- Trial name
- QUALICIS (NCT00819897)
- Where
- 17 sites in France
- Volunteers
- 37 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
The purpose of this study is to further evaluate the safety and efficacy of Tovaxin in the treatment of relapsing forms of multiple sclerosis.
- Trial name
- OLTERMS (NCT00595920)
- Testing
- Tovaxin
- Where
- 27 sites in United States
- Volunteers
- 116 people
- Sponsor
- Opexa Therapeutics, Inc.
Clinically Isolated Syndrome (CIS), Multiple Sclerosis (MS)
Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases
This a retrospective, blinded trial in which collaborators in Italy will review the doppler findings from the Combined Transcranial and Extracranial Venous Doppler (CTEVD) trial in an attempt to measure reproducibility.
- Conditions
- Clinically Isolated Syndrome (CIS), Multiple Sclerosis (MS), Other Neurological Disorders (OND), Healthy (HC)
- Trial name
- NCT02308579
- Volunteers
- 499 people
- Sponsor
- University at Buffalo
Clinically Isolated Syndrome
A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome
The primary objective of this initiative is to assess the effectiveness of subcutaneous (sc) interferon (IFN) beta - 1a, (Rebif®), versus No Treatment in delaying the conversion to Clinically Definite Multiple Sclerosis (CDMS) …
- Trial name
- CIS-ON (NCT00287079)
- Testing
- Rebif®, No Treatment
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-remitting Multiple Sclerosis, Clinically Isolated Syndrome
Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS
The purpose of the study is to determine whether giving intravenous dexamethasone every 4 weeks during the first 12 months of weekly Avonex dosing will reduce the progression of functional impairment, brain atrophy, relapse rate…
- Trial name
- NCT00232193
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Providence Multiple Sclerosis Center
Multiple Sclerosis, MS, Clinically Isolated Syndrome
Cohort Study of Clinically Isolated Syndrome and Early Multiple Sclerosis
A majority of patients with multiple sclerosis initially presents with a single demyelinating event, e.g. in the optic nerves, brain, brainstem or spinal cord, referred to as a clinically isolated syndrome (CIS).
- Trial name
- CIS-COHORT (NCT01371071)
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Charite University, Berlin, Germany